YR0160
Human PTK7 Monoclonal Antibody
Größe
£355.00
- SKU:
- YR0160
- Zusätzliche Namen:
- CCK-4, CCK4
- Anwendung:
- ELISA, FuncS, Neutralisation
- Molekulargewicht:
- 150 kDa
- Reinheit:
- >95%
- Lagerbedingungen:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- Abclonal
- Immunogen:
- Human PTK7
- Formulierung:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- Q13308
- Synonyme:
- CCK-4;CCK4;colon carcinoma kinase 4;inactive tyrosine-protein kinase 7;Protein-tyrosine kinase 7;pseudo tyrosine kinase receptor 7;PTK7 protein tyrosine kinase 7;tyrosine-protein kinase-like 7
- Weitere Details:
- What is cofetuzumab biosimilar research grade? Cofetuzumab is a humanized IgG1-kappa monoclonal antibody against PTK7, which is a tumor-associated antigen (TAA) and overexpressed on a variety of cancer cells. Cofetuzumab pelidotin is an antibody-drug conjugate (ADC) composed of cofetuzumab linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. Cofetuzumab biosimilar uses the same protein sequences as the therapeutic antibody cofetuzumab.
- Versandbedingungen:
- Blue Ice